Blue background

Pipeline and Clinical Trials

Corcept Sponsored Trials

Cushing’s Syndrome

Target Indication (Study Name)
Compound
Phase I
Phase II
Phase III
Target Indication (Study Name)
Endogenous Cushing syndrome (GRACE)
Compound
Relacorilant
Currently in Phase Three
Target Indication (Study Name)
Hypercortisolism associated with adrenal adenoma or hyperplasia (GRADIENT)
Compound
Relacorilant
Currently in Phase Three
Target Indication (Study Name)
Extension study to evaluate long term safety
Compound
Relacorilant
Phase Two

Oncology

Target Indication (Study Name)
Compound
Phase I
Phase II
Phase III
Target Indication (Study Name)
Platinum-resistant ovarian cancer (ROSELLA)
Compound
Relacorilant + Abraxane (nab-paclitaxel)
Currently in Phase Three
Target Indication (Study Name)
Adrenal cancer with cortisol excess
Compound
Relacorilant + Keytruda (pembrolizumab)
Phase One

Metabolic Diseases

Target Indication (Study Name)
Compound
Phase I
Phase II
Phase III
Target Indication (Study Name)
Recent antipsychotic-induced weight gain (GRATITUDE)
Compound
Miricorilant
Phase Two
Target Indication (Study Name)
Long-standing antipsychotic-induced weight gain (GRATITUDE II)
Compound
Miricorilant
Phase Two
Target Indication (Study Name)
NASH
Compound
Miricorilant
Phase One

Neurology

Target Indication (Study Name)
Compound
Phase I
Phase II
Phase III
Target Indication (Study Name)
ALS (DAZALS)
Compound
Dazucorilant
Phase Two

Investigator Sponsored Trials

Oncology

Target Indication
Compound
Phase I
Phase II
Phase III
Target Indication
Triple-negative breast cancer
Compound
Mifepristone + Abraxane (nab-paclitaxel)1
Phase Two
Target Indication
Prostate cancer
Compound
Relacorilant + Xtandi (enzalutamide)1
Phase Two

Addiction

Target Indication
Compound
Phase I
Phase II
Phase III
Target Indication
Alcohol use disorder
Compound
Miricorilant + Behavioral Therapy2
Phase Two

Psychiatry

Target Indication
Compound
Phase I
Phase II
Phase III
Target Indication
Alzheimer’s disease
Compound
CORT1082973
Phase Two
Target Indication
PTSD
Compound
CORT1082974
Phase Two
Target Indication
Major depression
Compound
Mifepristone5
Phase Two

Additional Areas of Research

Alzheimer’s disease
Anxiety
Diabetes
Hypertension
Neurodegenerative diseases
Nonsmall cell lung cancer
Obesity

GR, glucocorticoid receptor; HER2, human epidermal growth factor receptor 2; Nab-paclitaxel, nanoparticle albumin-bound paclitaxel; NASH, nonalcoholic steatohepatitis.

1University of Chicago.
2Scripps Research Institute and the National Institute on Alcohol Abuse and Alcoholism.
3John Hopkins University.

4VA Office of Research and Development.
5Amsterdam UMC.

Corcept's Clinical Trials

View Information on Clinical Trials

Clinical Trials